Breaking News
Self-Amplifying RNA Shots Are Coming: The Untold Danger
The global battle over microchips | DW Documentary
Israel BURYING Burned Cars They Attacked On October 7!
FBI, CDC refused to investigate Chinese biolab in California...
Top Tech News
China plans to mass produce humanoid robots in two years -
World's largest airship is unveiled:
Did He Lie? Lawmakers Request Investigation on Elon Musk's -
These $4,000 homes are keeping families in the Pine Ridge Native American Reservation...
How to Make Free Gas with Garbage | Free Gas Butane - Propane | Liberty BioGas
Gravity tests head-tracking, shoulder-mounted firearms on its jet suit
Incredible Fastest Wooden House Construction - Faster And Less Inexpensive Construction Solutions
Amazing Lego-Style HEMP BLOCKS Make Building a House Quick, Easy & Sustainable
Optimized Nuclear Thermal Rocket for 45 Days to Mars
New 10 Minute Treatment Restores Sense of Smell and Taste in Patients with COVID Parosmia
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.